
    
      This is a phase II, multicentric, open-label, non-randomized study, evaluating the efficacy
      of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP
      regimen during 4 cycles in patients aged 18 to 60 years with previously untreated CD20+
      diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor of the
      age-adjusted international prognostic index (Aa-IPI), and eligible for transplant.

      It is anticipated that 60 subjects will be enrolled over 2 years (from 2004 to 2006), in a
      group sequential manner one planned interim analysis.

      The duration of the treatment period is approximately 26 weeks and patients are followed
      until Death.

      The total Duration of the study is expected to be 2.5 years.
    
  